Atopic dermatitis (eczema): who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• JAK 7
• IL-4 1
• IL-13 2
• STAT3 1
• MAPK 0
• TNF 0
• PDE4 1
• TSLP 0
• NLRP3 0
• PPAR 0
• IL-6 0
• NRF2 0
• GLP-1 0
• AKT 0
• FOXP3 0
• HMGB1 0
• JNK 0
• STING 1
• ERK 0
• HSP90 0
• IL-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• TYK2 0
• YAP 0
• CD19 0
• CTLA-4 0
• CTNNB1 0
• FAK 0
• PD-1 0
• TLR4 0
• AMPK 0
• BCL-2 0
• CD38 0
• COX-2 0
• CXCR4 0
• DPP-4 0
• EGFR 0
• FTO 0
• G6PD 0
• HIF-1 0
• IL-15 0
• IL-23 0
• MEK 0
• PD-L1 0
• PINK1 0
• PTEN 0
• RANKL 0

18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  CUtibacterium acnes metabolic engineering for Therapeutic Indole in situ delivery in atopic dermatitis SKIN (CUTISKIN)

  Imperial College of Science Technology and Medicine· London, United Kingdom· EU contribution €276,188· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Netherlands· EU contribution €150,000· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Role of prenatal stress-induced fetal neuro-immune rewiring in susceptibility to develop pediatric eczema (PRENATALL)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €2,857,135· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatio-temporal integration of skin inflammation (4D-SkINFLAM)

  Deutsches Rheuma Forschungszentrumberlin· Berlin, Germany· EU contribution €2,499,188· until Sept 2028

  The disease is named only in the funder's project summary, not in the title.

5 of 8 running projects, newest first. Listed amounts together: €12.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT05250115· Pfizer· Updated 29 Sept 2025

  “Business decision: Due to the slow recruitment, the sponsor decided to discontinue the study early.”Registry text, quoted unchanged. Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

  NCT05219864· Incyte Corporation· Updated 17 Nov 2022

  “Business decision; no safety concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

  NCT05233410· Incyte Corporation· Updated 10 Nov 2022

  “Business decision; no safety concerns”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Incyte Corporation· Source

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· Sanofi· Source

• Tofacitinib for Immune Skin Conditions in Down Syndrome

  NCT04246372· University of Colorado, Denver· Source

• Topical Ruxolitinib Evaluation in Chronic Hand Eczema

  NCT05906628· Incyte Corporation· Source

• Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Incyte Corporation· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 2
• Mendelian Randomization Analysis 26
• Gene Expression Profiling 43
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 19
• Metabolomics 11
• Mass Spectrometry 1
• Flow Cytometry 7
• Immunohistochemistry 6
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 2
• Machine Learning 20
• Cohort Studies 65
• Genome-Wide Association Study 28

• Whole Genome Sequencing Reveals Antibiotic Resistance Heterogeneity and Metabolic Signatures of Cutibacterium acnes in Atopic Dermatitis.

  Curr Microbiol, Sept 2026

• Strain-Level Differences of Bifidobacterium breve in the Gut Microbiome between Infants with and without Atopic Dermatitis: Insights from Genome Analysis and Immune Assays.

  J Microbiol Biotechnol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.